Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

Core Insights - Genenta Science is participating in a significant event focused on biotechnology investments and strategies, highlighting the importance of international collaboration in the sector [1][2] - The CEO of Genenta, Pierluigi Paracchi, emphasizes the need for Italy to leverage its scientific heritage to enhance the application of biotechnologies and attract foreign investments [2][3] Company Overview - Genenta Science is a clinical-stage biotechnology company developing a proprietary hematopoietic stem cell therapy aimed at treating various solid tumor cancers [3] - The company's lead product, Temferon™, utilizes ex-vivo gene transfer into autologous Tie2+ hematopoietic stem/progenitor cells to deliver immunomodulatory molecules directly to tumors [3] Clinical Development - Temferon is currently under investigation in a clinical trial for newly diagnosed Glioblastoma Multiforme patients with an unmethylated MGMT gene promoter [3] - Genenta plans to initiate a Phase 1 clinical trial for metastatic Renal Cell Carcinoma, addressing significant challenges in immuno-oncology such as inducing durable immune responses and avoiding systemic toxicity [3]